Mim8 does not affect FVIII function in hemophilia A - ISTH Congress Abstracts
Novo Nordisk prepares phase III trial of potential blockbuster drug — MedWatch
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys - ScienceDirect
Novo makes a rare disease push | Evaluate
Pharmaceuticals | Free Full-Text | Updates on Novel Non-Replacement Drugs for Hemophilia
Mette Loftager's research works | Novo Nordisk, Copenhagen and other places
Marianne Kjalke's research works | Novo Nordisk, Copenhagen and other places
A multiple ascending dose study of Mim8 in patients with severe haemophilia A with or without factor VIII inhibitors
Mim8 Well-tolerated in Early Study, Paving Way for Phase 3 Hem A Trials | Hemophilia A Clinical Trials for Mim8 Supported by Early Results | Hemophilia News Today
Novo's attempt to snatch Roche's hemophilia crown gets serious
A Novel FVIIIa-Mimetic Bispecific Antibody, Mim8, Enhances FIXa Proteolytic Activity While Allowing for Efficient, Lipid-Dependent Assembly with FX - ISTH Congress Abstracts
Study Set to Assess Mim8 Therapy in People With Hemophilia A
ISTH 2022 – Novo moves forward with its Hemlibra rival | Evaluate
A novel next‐generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys - Lauritzen - 2022 - Journal of Thrombosis and
Hemophilia Clinical Research Trials | CenterWatch
Mim8 data sees potential as once monthly treatment for haemophilia A - European Pharmaceutical Manufacturer
